img

Global Live Attenuated Measles Vaccine Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Live Attenuated Measles Vaccine Market Insights, Forecast to 2034

The global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Live Attenuated Measles Vaccine include GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic and Medimmune, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic and Medimmune, etc.



By Company


GSK
Sanofi-Pasteur
Merck
Pfizer
Serum Institute of India
Novartis
Emergent Biosolutions
Bavarian Nordic
Medimmune
Johnson & Johnson
CSL Limited
Changchun Qijian Biological Products Co., Ltd
Beijing Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Segment by Type
Liquid
Powder

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Live Attenuated Measles Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Measles Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Live Attenuated Measles Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Liquid
1.2.3 Powder
1.3 Market by Application
1.3.1 Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts 2018-2034
2.2 Global Live Attenuated Measles Vaccine Revenue by Region
2.2.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Live Attenuated Measles Vaccine Revenue by Region (2018-2024)
2.2.3 Global Live Attenuated Measles Vaccine Revenue by Region (2024-2034)
2.2.4 Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2018-2034)
2.3 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts 2018-2034
2.4 Global Live Attenuated Measles Vaccine Sales by Region
2.4.1 Global Live Attenuated Measles Vaccine Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Live Attenuated Measles Vaccine Sales by Region (2018-2024)
2.4.3 Global Live Attenuated Measles Vaccine Sales by Region (2024-2034)
2.4.4 Global Live Attenuated Measles Vaccine Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Live Attenuated Measles Vaccine Sales by Manufacturers
3.1.1 Global Live Attenuated Measles Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Live Attenuated Measles Vaccine in 2022
3.2 Global Live Attenuated Measles Vaccine Revenue by Manufacturers
3.2.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Live Attenuated Measles Vaccine Revenue in 2022
3.3 Global Key Players of Live Attenuated Measles Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Live Attenuated Measles Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Live Attenuated Measles Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Live Attenuated Measles Vaccine Sales by Type
4.1.1 Global Live Attenuated Measles Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Live Attenuated Measles Vaccine Forecasted Sales by Type (2024-2034)
4.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Live Attenuated Measles Vaccine Revenue by Type
4.2.1 Global Live Attenuated Measles Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Live Attenuated Measles Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Live Attenuated Measles Vaccine Price by Type
4.3.1 Global Live Attenuated Measles Vaccine Price by Type (2018-2024)
4.3.2 Global Live Attenuated Measles Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Live Attenuated Measles Vaccine Sales by Application
5.1.1 Global Live Attenuated Measles Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Live Attenuated Measles Vaccine Forecasted Sales by Application (2024-2034)
5.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Live Attenuated Measles Vaccine Revenue by Application
5.2.1 Global Live Attenuated Measles Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Live Attenuated Measles Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Live Attenuated Measles Vaccine Price by Application
5.3.1 Global Live Attenuated Measles Vaccine Price by Application (2018-2024)
5.3.2 Global Live Attenuated Measles Vaccine Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Live Attenuated Measles Vaccine Market Size by Type
6.1.1 US & Canada Live Attenuated Measles Vaccine Sales by Type (2018-2034)
6.1.2 US & Canada Live Attenuated Measles Vaccine Revenue by Type (2018-2034)
6.2 US & Canada Live Attenuated Measles Vaccine Market Size by Application
6.2.1 US & Canada Live Attenuated Measles Vaccine Sales by Application (2018-2034)
6.2.2 US & Canada Live Attenuated Measles Vaccine Revenue by Application (2018-2034)
6.3 US & Canada Live Attenuated Measles Vaccine Market Size by Country
6.3.1 US & Canada Live Attenuated Measles Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Live Attenuated Measles Vaccine Sales by Country (2018-2034)
6.3.3 US & Canada Live Attenuated Measles Vaccine Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Live Attenuated Measles Vaccine Market Size by Type
7.1.1 Europe Live Attenuated Measles Vaccine Sales by Type (2018-2034)
7.1.2 Europe Live Attenuated Measles Vaccine Revenue by Type (2018-2034)
7.2 Europe Live Attenuated Measles Vaccine Market Size by Application
7.2.1 Europe Live Attenuated Measles Vaccine Sales by Application (2018-2034)
7.2.2 Europe Live Attenuated Measles Vaccine Revenue by Application (2018-2034)
7.3 Europe Live Attenuated Measles Vaccine Market Size by Country
7.3.1 Europe Live Attenuated Measles Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Live Attenuated Measles Vaccine Sales by Country (2018-2034)
7.3.3 Europe Live Attenuated Measles Vaccine Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Live Attenuated Measles Vaccine Market Size
8.1.1 China Live Attenuated Measles Vaccine Sales (2018-2034)
8.1.2 China Live Attenuated Measles Vaccine Revenue (2018-2034)
8.2 China Live Attenuated Measles Vaccine Market Size by Application
8.2.1 China Live Attenuated Measles Vaccine Sales by Application (2018-2034)
8.2.2 China Live Attenuated Measles Vaccine Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Live Attenuated Measles Vaccine Market Size by Type
9.1.1 Asia Live Attenuated Measles Vaccine Sales by Type (2018-2034)
9.1.2 Asia Live Attenuated Measles Vaccine Revenue by Type (2018-2034)
9.2 Asia Live Attenuated Measles Vaccine Market Size by Application
9.2.1 Asia Live Attenuated Measles Vaccine Sales by Application (2018-2034)
9.2.2 Asia Live Attenuated Measles Vaccine Revenue by Application (2018-2034)
9.3 Asia Live Attenuated Measles Vaccine Sales by Region
9.3.1 Asia Live Attenuated Measles Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Live Attenuated Measles Vaccine Revenue by Region (2018-2034)
9.3.3 Asia Live Attenuated Measles Vaccine Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Overview
11.1.3 GSK Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 GSK Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GSK Recent Developments
11.2 Sanofi-Pasteur
11.2.1 Sanofi-Pasteur Company Information
11.2.2 Sanofi-Pasteur Overview
11.2.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi-Pasteur Recent Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Overview
11.3.3 Merck Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Merck Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Pfizer Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Serum Institute of India
11.5.1 Serum Institute of India Company Information
11.5.2 Serum Institute of India Overview
11.5.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Serum Institute of India Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute of India Recent Developments
11.6 Novartis
11.6.1 Novartis Company Information
11.6.2 Novartis Overview
11.6.3 Novartis Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Novartis Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Novartis Recent Developments
11.7 Emergent Biosolutions
11.7.1 Emergent Biosolutions Company Information
11.7.2 Emergent Biosolutions Overview
11.7.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Emergent Biosolutions Recent Developments
11.8 Bavarian Nordic
11.8.1 Bavarian Nordic Company Information
11.8.2 Bavarian Nordic Overview
11.8.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bavarian Nordic Recent Developments
11.9 Medimmune
11.9.1 Medimmune Company Information
11.9.2 Medimmune Overview
11.9.3 Medimmune Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Medimmune Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Medimmune Recent Developments
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Information
11.10.2 Johnson & Johnson Overview
11.10.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Johnson & Johnson Recent Developments
11.11 CSL Limited
11.11.1 CSL Limited Company Information
11.11.2 CSL Limited Overview
11.11.3 CSL Limited Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 CSL Limited Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 CSL Limited Recent Developments
11.12 Changchun Qijian Biological Products Co., Ltd
11.12.1 Changchun Qijian Biological Products Co., Ltd Company Information
11.12.2 Changchun Qijian Biological Products Co., Ltd Overview
11.12.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
11.13 Beijing Institute of Biological Products Co., Ltd
11.13.1 Beijing Institute of Biological Products Co., Ltd Company Information
11.13.2 Beijing Institute of Biological Products Co., Ltd Overview
11.13.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
11.14 Wuhan Institute of Biological Products Co., Ltd
11.14.1 Wuhan Institute of Biological Products Co., Ltd Company Information
11.14.2 Wuhan Institute of Biological Products Co., Ltd Overview
11.14.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
11.15 Shanghai Institute of Biological Products Co., Ltd
11.15.1 Shanghai Institute of Biological Products Co., Ltd Company Information
11.15.2 Shanghai Institute of Biological Products Co., Ltd Overview
11.15.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
11.16 Lanzhou Institute of Biological Products Co., Ltd
11.16.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
11.16.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.16.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Live Attenuated Measles Vaccine Industry Chain Analysis
12.2 Live Attenuated Measles Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Live Attenuated Measles Vaccine Production Mode & Process
12.4 Live Attenuated Measles Vaccine Sales and Marketing
12.4.1 Live Attenuated Measles Vaccine Sales Channels
12.4.2 Live Attenuated Measles Vaccine Distributors
12.5 Live Attenuated Measles Vaccine Customers
13 Market Dynamics
13.1 Live Attenuated Measles Vaccine Industry Trends
13.2 Live Attenuated Measles Vaccine Market Drivers
13.3 Live Attenuated Measles Vaccine Market Challenges
13.4 Live Attenuated Measles Vaccine Market Restraints
14 Key Findings in The Global Live Attenuated Measles Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Liquid
Table 3. Major Manufacturers of Powder
Table 4. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Live Attenuated Measles Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Live Attenuated Measles Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Live Attenuated Measles Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Live Attenuated Measles Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Live Attenuated Measles Vaccine Sales by Region (2024-2034) & (K Units)
Table 13. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Live Attenuated Measles Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Live Attenuated Measles Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Live Attenuated Measles Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Live Attenuated Measles Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Live Attenuated Measles Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Measles Vaccine as of 2022)
Table 23. Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Live Attenuated Measles Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 29. Global Live Attenuated Measles Vaccine Sales Share by Type (2018-2024)
Table 30. Global Live Attenuated Measles Vaccine Sales Share by Type (2024-2034)
Table 31. Global Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Live Attenuated Measles Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Live Attenuated Measles Vaccine Revenue Share by Type (2024-2034)
Table 35. Live Attenuated Measles Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Live Attenuated Measles Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 39. Global Live Attenuated Measles Vaccine Sales Share by Application (2018-2024)
Table 40. Global Live Attenuated Measles Vaccine Sales Share by Application (2024-2034)
Table 41. Global Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Live Attenuated Measles Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Live Attenuated Measles Vaccine Revenue Share by Application (2024-2034)
Table 45. Live Attenuated Measles Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Live Attenuated Measles Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 56. US & Canada Live Attenuated Measles Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Live Attenuated Measles Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 60. Europe Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 62. Europe Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 66. Europe Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 69. Europe Live Attenuated Measles Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Live Attenuated Measles Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. China Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 75. China Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 79. China Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 83. Asia Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 87. Asia Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 90. Asia Live Attenuated Measles Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Live Attenuated Measles Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Live Attenuated Measles Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Live Attenuated Measles Vaccine Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales by Country (2024-2034) & (K Units)
Table 107. GSK Company Information
Table 108. GSK Description and Major Businesses
Table 109. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. GSK Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. GSK Recent Developments
Table 112. Sanofi-Pasteur Company Information
Table 113. Sanofi-Pasteur Description and Major Businesses
Table 114. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Sanofi-Pasteur Recent Developments
Table 117. Merck Company Information
Table 118. Merck Description and Major Businesses
Table 119. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Merck Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Merck Recent Developments
Table 122. Pfizer Company Information
Table 123. Pfizer Description and Major Businesses
Table 124. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Pfizer Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Pfizer Recent Developments
Table 127. Serum Institute of India Company Information
Table 128. Serum Institute of India Description and Major Businesses
Table 129. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Serum Institute of India Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Serum Institute of India Recent Developments
Table 132. Novartis Company Information
Table 133. Novartis Description and Major Businesses
Table 134. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Novartis Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Novartis Recent Developments
Table 137. Emergent Biosolutions Company Information
Table 138. Emergent Biosolutions Description and Major Businesses
Table 139. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Emergent Biosolutions Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Emergent Biosolutions Recent Developments
Table 142. Bavarian Nordic Company Information
Table 143. Bavarian Nordic Description and Major Businesses
Table 144. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Bavarian Nordic Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Bavarian Nordic Recent Developments
Table 147. Medimmune Company Information
Table 148. Medimmune Description and Major Businesses
Table 149. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Medimmune Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Medimmune Recent Developments
Table 152. Johnson & Johnson Company Information
Table 153. Johnson & Johnson Description and Major Businesses
Table 154. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Johnson & Johnson Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Johnson & Johnson Recent Developments
Table 157. CSL Limited Company Information
Table 158. CSL Limited Description and Major Businesses
Table 159. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. CSL Limited Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. CSL Limited Recent Developments
Table 162. Changchun Qijian Biological Products Co., Ltd Company Information
Table 163. Changchun Qijian Biological Products Co., Ltd Description and Major Businesses
Table 164. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Changchun Qijian Biological Products Co., Ltd Recent Developments
Table 167. Beijing Institute of Biological Products Co., Ltd Company Information
Table 168. Beijing Institute of Biological Products Co., Ltd Description and Major Businesses
Table 169. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Beijing Institute of Biological Products Co., Ltd Recent Developments
Table 172. Wuhan Institute of Biological Products Co., Ltd Company Information
Table 173. Wuhan Institute of Biological Products Co., Ltd Description and Major Businesses
Table 174. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Wuhan Institute of Biological Products Co., Ltd Recent Developments
Table 177. Shanghai Institute of Biological Products Co., Ltd Company Information
Table 178. Shanghai Institute of Biological Products Co., Ltd Description and Major Businesses
Table 179. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Shanghai Institute of Biological Products Co., Ltd Recent Developments
Table 182. Lanzhou Institute of Biological Products Co., Ltd Company Information
Table 183. Lanzhou Institute of Biological Products Co., Ltd Description and Major Businesses
Table 184. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
Table 187. Key Raw Materials Lists
Table 188. Raw Materials Key Suppliers Lists
Table 189. Live Attenuated Measles Vaccine Distributors List
Table 190. Live Attenuated Measles Vaccine Customers List
Table 191. Live Attenuated Measles Vaccine Market Trends
Table 192. Live Attenuated Measles Vaccine Market Drivers
Table 193. Live Attenuated Measles Vaccine Market Challenges
Table 194. Live Attenuated Measles Vaccine Market Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Live Attenuated Measles Vaccine Product Picture
Figure 2. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Live Attenuated Measles Vaccine Market Share by Type in 2022 & 2034
Figure 4. Liquid Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Live Attenuated Measles Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Live Attenuated Measles Vaccine Report Years Considered
Figure 11. Global Live Attenuated Measles Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Live Attenuated Measles Vaccine Revenue 2018-2034 (US$ Million)
Figure 13. Global Live Attenuated Measles Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2018-2034)
Figure 15. Global Live Attenuated Measles Vaccine Sales 2018-2034 ((K Units)
Figure 16. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2018-2034)
Figure 17. US & Canada Live Attenuated Measles Vaccine Sales YoY (2018-2034) & (K Units)
Figure 18. US & Canada Live Attenuated Measles Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Live Attenuated Measles Vaccine Sales YoY (2018-2034) & (K Units)
Figure 20. Europe Live Attenuated Measles Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Live Attenuated Measles Vaccine Sales YoY (2018-2034) & (K Units)
Figure 22. China Live Attenuated Measles Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Asia (excluding China) Live Attenuated Measles Vaccine Sales YoY (2018-2034) & (K Units)
Figure 24. Asia (excluding China) Live Attenuated Measles Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Live Attenuated Measles Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Live Attenuated Measles Vaccine in the World: Market Share by Live Attenuated Measles Vaccine Revenue in 2022
Figure 29. Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 31. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 32. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 33. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 34. US & Canada Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 35. US & Canada Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 36. US & Canada Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 37. US & Canada Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 38. US & Canada Live Attenuated Measles Vaccine Revenue Share by Country (2018-2034)
Figure 39. US & Canada Live Attenuated Measles Vaccine Sales Share by Country (2018-2034)
Figure 40. U.S. Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 41. Canada Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 42. Europe Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 43. Europe Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 44. Europe Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 45. Europe Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 46. Europe Live Attenuated Measles Vaccine Revenue Share by Country (2018-2034)
Figure 47. Europe Live Attenuated Measles Vaccine Sales Share by Country (2018-2034)
Figure 48. Germany Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 49. France Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 50. U.K. Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 51. Italy Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 52. Russia Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. China Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 54. China Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 55. China Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 56. China Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 57. Asia Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 58. Asia Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 59. Asia Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 60. Asia Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 61. Asia Live Attenuated Measles Vaccine Revenue Share by Region (2018-2034)
Figure 62. Asia Live Attenuated Measles Vaccine Sales Share by Region (2018-2034)
Figure 63. Japan Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 64. South Korea Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 65. China Taiwan Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 66. Southeast Asia Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 67. India Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales Market Share by Type (2018-2034)
Figure 69. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue Market Share by Type (2018-2034)
Figure 70. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales Market Share by Application (2018-2034)
Figure 71. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue Market Share by Application (2018-2034)
Figure 72. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Revenue Share by Country (2018-2034)
Figure 73. Middle East, Africa and Latin America Live Attenuated Measles Vaccine Sales Share by Country (2018-2034)
Figure 74. Brazil Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Mexico Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Turkey Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Israel Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. GCC Countries Live Attenuated Measles Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Live Attenuated Measles Vaccine Value Chain
Figure 80. Live Attenuated Measles Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed